Clinical Trial Update: Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing pharmacodynamics and safety of coadministered DGAT2 inhibitor and ACC inhibitor in participants with presumed nonalcoholic stea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• ACCi
• DGAT2 inhibitor

Snippet

Sponsor: Pfizer | Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-04-13